Technology
Health
Biotechnology

Champions Oncology

$10.65
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.49 (-4.40%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CSBR and other stocks, options, ETFs, and crypto commission-free!

About

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. Read More It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Employees
92
Headquarters
Hackensack, New Jersey
Founded
1985
Market Cap
127.83M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
117.94K
High Today
$11.43
Low Today
$10.37
Open Price
$11.27
Volume
29.06K
52 Week High
$17.90
52 Week Low
$3.37

Collections

Technology
Health
Biotechnology
Cancer Prevention
Pharmaceutical
US
North America

News

Seeking AlphaMar 18

Champions Oncology, Inc (CSBR) CEO Ronnie Morris on Q3 2019 Results - Earnings Call Transcript

Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2019 Earnings Conference Call March 18, 2019 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Paul Knight - Janney Montgomery Scott Unidentified Analyst - Unidentified Analyst - Unidentified Analyst - Operator Greetings, welcome to Champions Oncology Third Quarter Fiscal Year 2019 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answ...

20
Yahoo FinanceMar 18

Champions Oncology Reports Quarterly Revenue of $6.4 Million

Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, NJ / ACCESSWIRE / March 18, 2019 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the third fiscal quarter ended January 31, 2019. Third Quarter and Recent Business Highlights: Quarterly revenue of $6.4 million, an increase of 26% year-over-y...

28
MarketBeatMar 7

Stock Price, News, & Analysis for Champions Oncology

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor ...

13

Earnings

-$0.05
-$0.02
$0.02
$0.05
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
$0.03 per share
Actual
$0.00 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.